Affiliation:
1. CBQF—Centro de Biotecnologia e Química Fina—Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, Rua Diogo Botelho 1327, 4169-005 Porto, Portugal
Abstract
Lipid molecules, such as policosanol, ergosterol, sphingomyelin, omega 3 rich phosphatidylcholine, α-tocopherol, and sodium butyrate, have emerged as novel additions to the portfolio of bioactive lipids. In this state-of-the-art review, we discuss these lipids, and their activity against obesity and mental or neurological disorders, with a focus on their proposed cellular targets and the ways in which they produce their beneficial effects. Furthermore, this available information is compared with that provided by in silico Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) models in order to understand the usefulness of these tools for the discovery of new bioactive compounds. Accordingly, it was possible to highlight how these lipids interact with various cellular targets related to the molecule transportation and absorption (e.g., α-tocopherol transfer protein for α-Tocopherol, ATP-binding cassette ABC transporters or Apolipoprotein E for sphingomyelins and phospholipids) or other processes, such as the regulation of gene expression (involving Sterol Regulatory Element-Binding Proteins for ergosterol or Peroxisome Proliferator-Activated Receptors in the case of policosanol) and inflammation (the regulation of interleukins by sodium butyrate). When comparing the literature with in silico Quantitative Structure–Activity Relationship (QSAR) models, it was observed that although they are useful for selecting bioactive molecules when compared in batch, the information they provide does not coincide when assessed individually. Our review highlights the importance of considering a broad range of lipids as potential bioactives and the need for accurate prediction of ADMET parameters in the discovery of new biomolecules. The information presented here provides a useful resource for researchers interested in developing new strategies for the treatment of obesity and mental or neurological disorders.
Funder
Amyris Bio Products Portugal Unipessoal Lda
Escola Superior de Biotecnologia—Universidade Católica Portuguesa
scientific collaboration
Subject
Plant Science,Health Professions (miscellaneous),Health (social science),Microbiology,Food Science
Reference172 articles.
1. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) (2016). Guideline on Clinical Evaluation of Medicinal Products Used in Weight Management, European Medicines Agency.
2. WHO Regional office for Europe (2022). WHO European Regional Obesity Report 2022, WHO Regional Office for Europe.
3. European Medicines Agency (2019). Reflection Paper on Regulatory Requirements for the Development of Medicinal Products for Chronic Non-Infectious Liver Diseases (PBC, PSC, NASH), European Medicines Agency.
4. Octacosanol and Policosanol Prevent High-Fat Diet-Induced Obesity and Metabolic Disorders by Activating Brown Adipose Tissue and Improving Liver Metabolism;Sharma;Sci. Rep.,2019
5. Decreased Membrane Fluidity and Altered Susceptibility to Peroxidation and Lipid Composition in Overweight and Obese Female Erythrocytes;Cazzola;J. Lipid Res.,2004
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献